- Home
- EMD vs CRMD Comparison
EMD vs CRMD Comparison
Compare EMD & CRMD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | EMD | CRMD |
|---|---|---|
| Founded | 2003 | 2006 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Finance/Investors Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 645.2M | 605.9M |
| IPO Year | N/A | 2009 |
Fundamental Metrics
Financial Performance| Metric | EMD | CRMD |
|---|---|---|
| Price | $11.02 | $7.14 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 7 |
| Target Price | N/A | ★ $15.29 |
| AVG Volume (30 Days) | 229.4K | ★ 1.5M |
| Earning Date | 01-01-0001 | 04-10-2026 |
| Dividend Yield | ★ 10.25% | N/A |
| EPS Growth | N/A | ★ 67.03 |
| EPS | N/A | ★ 1.97 |
| Revenue | N/A | ★ $43,472,170.00 |
| Revenue This Year | N/A | $627.64 |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | $3.75 |
| Revenue Growth | N/A | ★ 66363.08 |
| 52 Week Low | $8.56 | $5.60 |
| 52 Week High | $11.30 | $17.43 |
Technical Indicators
Market Signals| Indicator | EMD | CRMD |
|---|---|---|
| Relative Strength Index (RSI) | 49.92 | 39.68 |
| Support Level | $10.22 | $6.55 |
| Resistance Level | $11.30 | $8.53 |
| Average True Range (ATR) | 0.12 | 0.26 |
| MACD | -0.03 | 0.08 |
| Stochastic Oscillator | 33.33 | 24.74 |
Price Performance
Historical ComparisonAbout EMD Western Asset Emerging Markets Debt Fund Inc
Western Asset Emg Markets Debt Fund Inc is a non-diversified closed-end management, and long term investment company. The primary investment objective of the company is to seek high current income and the secondary objective is to seek capital appreciation.
About CRMD CorMedix Inc.
Cormedix Inc is a biopharmaceutical company focused on developing and commercializing therapeutic products for life-threatening diseases and conditions. The Company's focus is on the commercialization of its product, DefenCath, in the United States (U.S.) and other key markets. The group currently operates in a single segment, Drug Product, located in a single geographic location, the United States.